Earnings Outlook For Iterum Therapeutics

Iterum Therapeutics (NASDAQ:ITRM) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here’s what investors…

Iterum Therapeutics (NASDAQ:ITRM) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here’s what investors need to know before the announcement.

Analysts estimate that Iterum Therapeutics will report an earnings per share (EPS) of $-0.91.

Iterum Therapeutics bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.03, which was followed by a 0.0% drop in the share price the next day.

Here’s a look at Iterum Therapeutics’s past performance and the resulting price change:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.80 -1.05
EPS Actual -0.77 -0.58 -0.52 -0.43
Price Change % 7.92% 0.88% -6.09% 4.55%

Stock Performance

Shares of Iterum Therapeutics were trading at $0.79 as of November 10. Over the last 52-week period, shares are down 47.29%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Iterum Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Robinhood Markets, Inc. Reports January 2024 Operating Data; Assets Under Custody At The End Of January Were $102.4B, Roughly Flat To December 2023; Trading Volumes In January Were Higher For Options, And Lower For Equities And Crypto Relative To Decem…

Robinhood Markets, Inc. ("Robinhood") (NASDAQ:HOOD) today reported selected monthly operating data for January 2024: Funded Customers at the end of January were 23.5 million, up approximately 120 thousand from

HOOD